A committee of outside advisers to the U.S. Food and Drug Administration (FDA) recommended a vaccine from GlaxoSmithKline (GSK) against the respiratory syncytial virus (RSV) for adults over age 60.
The vote from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) for GSK’s Arexvy (RSVPreF3-AS01) vaccine comes a day after the 12 members voted to endorse Pfizer’s vaccine candidate, Abrysvo (RSVPreF), for the same age group.
For both vaccines, the members flagged potential safety concerns especially with regard to Guillain-Barré syndrome, a neurological disorder in which the body’s nerves are compromised, symptoms of which can range from brief weakness in limbs, to paralysis all over the body. But most people recover, even in severe cases….